SM Swain

536 total citations
21 papers, 287 citations indexed

About

SM Swain is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, SM Swain has authored 21 papers receiving a total of 287 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 16 papers in Cancer Research and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in SM Swain's work include Breast Cancer Treatment Studies (13 papers), Advanced Breast Cancer Therapies (11 papers) and HER2/EGFR in Cancer Research (10 papers). SM Swain is often cited by papers focused on Breast Cancer Treatment Studies (13 papers), Advanced Breast Cancer Therapies (11 papers) and HER2/EGFR in Cancer Research (10 papers). SM Swain collaborates with scholars based in United States, Italy and United Kingdom. SM Swain's co-authors include CE Geyer, EP Mamounas, Norman Wolmark, José Baselga, Soonmyung Paik, Emma Clark, Priya Rastogi, S-A Im, Gill Ross and Astrid Kiermaier and has published in prestigious journals such as Cancer Research.

In The Last Decade

SM Swain

20 papers receiving 282 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
SM Swain United States	9	237	136	109	66	40	21	287
MF Press United States	9	233 1.0×	74 0.5×	117 1.1×	54 0.8×	92 2.3×	30	279
Marcelle Goldner Cesca Brazil	6	223 0.9×	99 0.7×	88 0.8×	76 1.2×	27 0.7×	18	272
C. Saura Manich Spain	8	229 1.0×	58 0.4×	105 1.0×	102 1.5×	29 0.7×	32	270
Rochelle Strenger United States	6	370 1.6×	164 1.2×	131 1.2×	60 0.9×	46 1.1×	19	414
Danai Fimereli Belgium	7	211 0.9×	140 1.0×	81 0.7×	67 1.0×	63 1.6×	10	294
Elisa Genovesi Italy	4	251 1.1×	157 1.2×	123 1.1×	75 1.1×	23 0.6×	6	289
CE Geyer United States	9	217 0.9×	148 1.1×	74 0.7×	71 1.1×	28 0.7×	23	262
Jason Mouabbi United States	7	113 0.5×	100 0.7×	51 0.5×	64 1.0×	24 0.6×	41	205
Clasina M. Venema Netherlands	9	133 0.6×	132 1.0×	165 1.5×	131 2.0×	38 0.9×	13	320
Lingzhu Wen China	10	181 0.8×	165 1.2×	50 0.5×	96 1.5×	153 3.8×	24	341

Countries citing papers authored by SM Swain

Since Specialization

Citations

This map shows the geographic impact of SM Swain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by SM Swain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites SM Swain more than expected).

Fields of papers citing papers by SM Swain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by SM Swain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by SM Swain. The network helps show where SM Swain may publish in the future.

Co-authorship network of co-authors of SM Swain

This figure shows the co-authorship network connecting the top 25 collaborators of SM Swain. A scholar is included among the top collaborators of SM Swain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with SM Swain. SM Swain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Khoury, Katia, Claudine Isaacs, Jeffrey Schlom, et al.. (2019). Abstract OT3-04-01: Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: The OXEL study. Cancer Research. 79(4_Supplement). OT3–4. 5 indexed citations

Obeid, Elias, Elizabeth A. Handorf, Lori J. Goldstein, et al.. (2018). Abstract PD6-03: Distribution of microsatellite instability, tumor mutational load, and PD-L1 status in molecularly profiled invasive breast cancer. Cancer Research. 78(4_Supplement). PD6–3. 9 indexed citations

Fehrenbacher, L., CE Geyer, Priya Rastogi, et al.. (2018). Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC). Cancer Research. 78(4_Supplement). GS1–2. 40 indexed citations

Swain, SM, Giuseppe Viale, Suzette Delaloge, et al.. (2017). Abstract P4-21-41: Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer. Cancer Research. 77(4_Supplement). P4–21. 3 indexed citations

Rastogi, Priya, CE Geyer, Louis Fehrenbacher, et al.. (2017). Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52. Cancer Research. 77(4_Supplement). S3–6. 29 indexed citations

Mamounas, EP, Hanna Bandos, BC Lembersky, et al.. (2017). Abstract S1-05: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): Results from NRG Oncology/NSABP B-42. Cancer Research. 77(4_Supplement). S1–5. 37 indexed citations

Lynce, Filipa, et al.. (2017). Abstract PD8-04: Racial differences in the molecular landscape of breast cancer. Cancer Research. 77(4_Supplement). PD8–4. 2 indexed citations

Swain, SM, Andreas Schneeweiß, Lorenzo Gianni, et al.. (2016). Abstract P4-14-14: Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Cancer Research. 76(4_Supplement). P4–14. 2 indexed citations

Swain, SM, et al.. (2016). Abstract OT3-03-01: Increasing participation in research - Breast cancer. Cancer Research. 76(4_Supplement). OT3–3.

10.

Swain, SM, J. P. Costantino, Priya Rastogi, et al.. (2013). Abstract PD2-1: Body mass index at diagnosis and breast cancer survival prognosis among clinical trial populations: Results from NSABP B-30, B-31, B-34, and B-38. Cancer Research. 73(24_Supplement). PD2–1. 1 indexed citations

11.

Romond, Edward H., VJ Suman, CE Geyer, et al.. (2012). Abstract S5-5: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831. Cancer Research. 72(24_Supplement). S5–5. 33 indexed citations

12.

Baselga, José, Javier Cortés, S-A Im, et al.. (2012). Abstract S5-1: Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). Cancer Research. 72(24_Supplement). S5–1. 46 indexed citations

13.

Swain, SM, S-B. Kim, Jungsil Ro, et al.. (2012). Abstract P5-18-26: Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC). Cancer Research. 72(24_Supplement). P5–18. 12 indexed citations

14.

Miles, David, José Baselga, D. Amadori, et al.. (2012). Abstract P5-18-01: Pertuzumab (P) in combination with trastuzumab (T) and docetaxel (D) in elderly patients with HER2-positive metastatic breast cancer in the CLEOPATRA study. Cancer Research. 72(24_Supplement). P5–18. 5 indexed citations

15.

Lembersky, BC, Louis Fehrenbacher, CI Falkson, et al.. (2011). S2-3: NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis.. Cancer Research. 71(24_Supplement). S2–3. 14 indexed citations

16.

Fehrenbacher, L., Priya Rastogi, CE Geyer, et al.. (2011). OT1-02-07: NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2−Low Invasive Breast Cancer.. Cancer Research. 71(24_Supplement). OT1–2. 3 indexed citations

17.

Vogel, C. L., K. Bloom, Howard A. Burris, et al.. (2011). P1-07-02: Discordance between Central and Local Laboratory HER2 Testing from a Large HER2−Negative Population in VIRGO, a Metastatic Breast Cancer Registry.. Cancer Research. 71(24_Supplement). P1–7. 8 indexed citations

18.

Baselga, José, S-B. Kim, S-A. Im, et al.. (2011). S5-5: A Phase III, Randomized, Double-Blind, Placebo-Controlled Registration Trial To Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Patients with Previously Untreated HER2−Positive Metastatic Breast Cancer (CLEOPATRA).. Cancer Research. 71(24_Supplement). S5–5. 8 indexed citations

19.

Swain, SM, Joon Jeong, CE Geyer, et al.. (2009). NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer.. Cancer Research. 69(2_Supplement). 75–75. 21 indexed citations

20.

Ganz, PA, CE Geyer, J. P. Costantino, et al.. (2009). NSABP B-30: definitive analysis of quality of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer.. Cancer Research. 69(2_Supplement). 76–76. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact